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IL-24, also known as melanoma differentiation antigen 7 (mda-7), is a member of the IL-10 family of cytokines and is mainly
produced by Th2 cells as well as by activated monocytes. Binding of IL-24 to either of its two possible heterodimeric receptors
IL-20R1/IL-20R2 and IL-22R/IL-20R2 activates STAT3 and/or STAT1 in target tissues such as lung, testis, ovary, keratinocytes and
skin. To date, the physiological properties of IL-24 are still not well understood but available data suggest that IL-24 affects
epidermal functions by increasing proliferation of dermal cells. In stark contrast to its ‘‘normal’’ and physiological behaviour,
IL-24 has been reported to selectively and efficiently kill a vast variety of cancer cells, especially melanoma cells, independent
of receptor expression and Jak-STAT signalling. These intriguing properties have led to the development of adenovirally-
expressed IL-24, which is currently being evaluated in clinical trials. Using three different methods, we have analysed a large
panel of melanoma cell lines with respect to IL-24 and IL-24 receptor expression and found that none of the investigated cell
lines expressed sufficient amounts of functional receptor pairs and therefore did not react to IL-24 stimulation with Jak/STAT
activation. Results for three cell lines contrasted with previous studies, which reported presence of IL-24 receptors and
activation of STAT3 following IL-24 stimulation. Furthermore, evaluating four different sources and modes of IL-24
administration (commercial recombinant IL-24, bacterially expressed GST-IL-24 fusion protein, IL-24 produced from transfected
Hek cells, transiently over-expressed IL-24) no induction or increase in cell death was detected when compared to appropriate
control treatments. Thus, we conclude that the cytokine IL-24 itself has no cancer-specific apoptosis-inducing properties in
melanoma cells.
Citation: Kreis S, Philippidou D, Margue C, Rolvering C, Haan C, et al (2007) Recombinant Interleukin-24 Lacks Apoptosis-Inducing Properties in
Melanoma Cells. PLoS ONE 2(12): e1300. doi:10.1371/journal.pone.0001300
INTRODUCTION
Interleukin (IL) -24 (mda-7), a member of the IL-10 family of
cytokines (together with IL-10, -19, -20, -22, and -26), has been
discovered in 1995 by subtraction hybridization following
‘‘differentiation therapy’’ of melanoma cells: through treatment
with IFN-b and a protein kinase C inhibitor (mezerein) neoplastic
melanoma cells terminally differentiate and lose their proliferative
capacity. By comparing gene expression profiles in treated versus
untreated cells, mda-7 (amongst others) was identified to be up-
regulated in non-proliferative and differentiated melanoma cells
[1]. In the following years it was shown that IL-24/mda-7 is
basally expressed in tissues related to the immune system (thymus,
spleen, macrophages and PBMC’s, especially in monocytes and T
cells), in normal melanocytes, and keratinocytes [2–5]. Genomic
localisation, sequence and structural comparisons, as well as
expression patterns, led to the renaming of mda-7 to IL-24 [6].
Thereafter it has been demonstrated that IL-24 is in fact a typical
cytokine as it binds to specific receptors, it is secreted, it activates
the JAK/STAT signaling pathway and it can modulate growth
characteristics of responsive cells [7–10].
IL-24 (and IL-20) interacts with two different heterodimeric
receptor complexes from the class II cytokine receptor family: IL-
20R1/IL-20R2 and IL-22R/IL-20R2. On receptor-expressing
cells, IL-24 activates the JAK-STAT pathway, shown by
phosphorylation of STAT3 [11,12]. However, the cellular targets
of IL-24-activated STAT3 transcription factors and the physio-
logical role of this IL-24-induced signalling remain to be clarified.
A recent and comprehensive study by Kunz and colleagues [2]
investigated the expression patterns of IL-24 and its receptor
chains by quantitative real-time PCR (qPCR). IL-24 was pre-
dominantly expressed by skin tissue cells during local subchronic
inflammation but not during acute inflammation. Also, IL-24
expression in skin samples from patients with psoriasis showed no
dramatic increase when compared to healthy skin from the same
patients. In contrast, IL-19 and IL-20 were strongly induced in
samples from patients with inflammatory skin disease while freshly
isolated keratinocytes expressed robust levels of IL-24 and IL-20.
Interestingly, immune cells did not express receptors for IL-24
suggesting that this cytokine cannot stimulate immune reactions by
directly interacting with cells from the immune system [2] but that it
rather exerts its functions on keratinocytes, inflamed skin and/or yet
unidentified target tissues. Apart from the physiological properties
that IL-24 may have under ‘‘normal’’ conditions, far more emphasis
has been placed on the tentative ability of this cytokine to selectively
induce apoptosis of cancer cells.
The first interest in IL-24 as a possible therapeutic agent for
cancercamefromobservationsthatIL-24transcriptsorproteinwere
gradually lost during advanced invasive progression of melanoma
[13,14]. Initial evidence on IL-24-induced apoptosis of cancer cells
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transfection of IL-24 into melanoma cells reduced colony numbers
while healthy cells remained unaffected by such a paradigm [1,15].
To improve modes of IL-24 delivery to various normal and cancer
cell types, a replication-deficient Adenovirus expressing IL-24/mda-
7 (Ad-mda7) was constructed, which, when applied to breast cancer
cells, induced selective apoptosis and inhibited breast cancer growth
in nude mice [16,17]. Since the first reports on this apoptosis-
inducing function of Ad-mda7 numerous studies have been
published demonstrating that IL-24, when administered in supra-
physiological amounts via an adenoviral vector, selectively and
efficiently kills cancer cell lines derived from breast, cervix, colon,
lung, prostate, glioma, melanoma, ovary, bone, and other sources
[10,16,18–25]. These remarkable findings have led to the de-
velopment of INGN 241 (Introgen), a replication-incompetent IL-
24-expressing adenovirus, which is currently in phaseII/III clinical
trials (Introgen, company homepage, [26]).
Despite this advanced stage of clinical testing many fundamen-
tal questions regarding the tentative IL-24-mediated selective
killing of cancer cells remain to be answered. For example,
conflicting data exist, concerning the effects of IL-24 expressed
and delivered by routes other than the adenoviral over-expression
system. IL-24 secreted from transfected human embryonic kidney
cells (Hek) was shown to elicit apoptosis of various cancer types in
vitro [16,27–30] while others reported that this form of IL-24 was
unable to alter growth characteristics of cancer cells (Caudell et al.,
2002; Pataer et al., 2005; Ramesh et al., 2003). Another source of
recombinant IL-24, a GST-fusion protein expressed in and
purified from E.coli bacteria, has been reported to kill prostate,
breast and pancreatic carcinoma cell lines [31,32], whereas others
[28,33] found no such attributes of GST-IL-24. In this context, it
remains completely unclear how these different recombinant
forms of IL-24 retain their deduced selectivity for cancer cells
while healthy cells are not affected or harmed.
Depending on the type of cancer under investigation many
different signalling molecules and pathways are believed to actively
partake in the IL-24-mediated killing of target cells (for comprehen-
sive reviews,see [34,35]).Nevertheless,several studies converge on an
UPR (unfolded protein response) or ER (endoplasmic reticulum)
stress response, triggered by a temporal over-expression of recombi-
nant IL-24 in the ER, which eventually promotes apoptosis of cancer
cells. Surprisingly, the same over-expression regimen does not appear
to harm healthy cells [8,33,36]. Adding yet another puzzling property
to this cytokine it has been reported that infection, transfection or
transduction of cells with full length IL-24 leads to secretion of
functional cytokine, which then elicits so-called ‘‘bystander’’ effects
killing surrounding (receptor-positive) cancer cells [28,37].
Incited by the tentatively beneficial traits of this IL-10-family
cytokine, we initially set out to investigate the signalling events
underlying IL-24-induced direct as well as ‘‘bystander’’ killing of
melanoma cells. To our surprise, from a panel of 12 different
melanoma cell lines, including A375, MeWo, and Wm35, which
had previously been described to express receptors for IL-24 and
to respond to IL-24 stimulation [28], none reacted to IL-24
stimulation with activation of STAT3. By means of RT-PCR,
qPCR, and western blot analysis we show that none of the tested
melanoma cell lines expresses a functional IL-24 receptor
complex. Finally and importantly, five different routes of IL-24
administration, including intracellular over-expression, were
evaluated for their potential to kill a selection of melanoma cell
lines. No increased apoptosis was observed in any of the tested
scenarios when compared to appropriate control treatments and
therefore we conclude that the cytokine IL-24 itself is not sufficient
to selectively drive melanoma cells into apoptosis.
RESULTS
Lack of Jak/STAT activation in melanoma cells
following stimulation with IL-24
Initially, a panel of 12 different melanoma cell lines, the
immortalised keratinocyte line HaCaT and primary human
melanocytes (NHEM), were evaluated for classic Jak-STAT
activation following IL-24 stimulation. In parallel, we analysed
related IL-10-type cytokines, IL-19 and IL-20. Fig. 1A shows that
none of the 3 recombinant cytokines had any effect on melanoma
cell lines, while OSM (lanes 2, positive control) induced a strong
phosphorylation of STAT3 in 10 out of 12 cell lines. Interestingly,
SKMel30 and IGR37 cells were reproducibly non-responsive to
OSM. In agreement with previous reports, HaCaT cells clearly
respond to IL-24 (lane 5), to a lesser extent to IL-20 (lane 4) and
very weakly to IL-19 (lane 3) [2,7]. Surprisingly, the melanoma cell
lines A375, MeWo, and Wm35 did not react to IL-24 although
previous studies had reported that IL-24 led to STAT3 activation
in these cells [28,29]. Additionally, IL-24 produced from
transfected Hek cell supernatants (lanes 6), which will be discussed
in more detail below, also induced phosphorylation of STAT3 in
HaCaT cells but not in any of the melanoma cell lines.
Interestingly, primary melanocytes (NHEM, at passage no. 4)
did not show an activation of STAT3 following stimulation with
the tested IL-10-type cytokines.
To determine if STAT activation, in response to these
recombinant cytokines follows a distinct kinetic, we stimulated 4
selected cell lines with 100 ng/ml of IL-24, IL-20, and IL-22 in
addition to control treatments with OSM and IFN-c over three
different periods of time (5, 30, and 180 min). Fig. 1B shows that IL-
20 and IL-24 had no effect on melanoma lines, while IL-22 induced
phosphorylation of STAT3 in A375 and Wm9 cells but not in
Wm35 or MeWo. Control treatments with OSM and IFN-c resulted
in the expected activation patterns of STAT3, 1, and 5 [38,39].
Focusing on IL-24, we then performed standard dose-response
and extended kinetic studies on HaCaT keratinocytes and the two
melanoma cell lines MeWo and Wm35. Fig. 2A illustrates that as
little as 25 ng/ml IL-24 led to a robust activation of STAT3 and to
a much lesser extent of STAT1 and 5 in responsive HaCaT cells.
However, concentrations as high as 800 ng/ml did not produce
any STAT phosphorylation in the two assayed melanoma cell
lines. Even upon heavy over-exposure of some of the western blots
did we not see potentially weak IL-24-induced P-STAT3 signals
(data not shown). The possibility of a delayed STAT activation
following IL-24 treatment was ruled out by incubating the cells for
up to 24 h (Fig. 2B). Control treatments with OSM showed
a typical STAT phosphorylation pattern, which decreases at
around 2h, the time when SOCS proteins (suppressor of cytokine
signalling) become active [40].
Expression of IL-24 and its receptors on melanoma
cells
Classic cytokine signalling events require the binding of a cytokine
to its receptor(s), an event which results in the transphosphoryla-
tion and activation of Jaks. Subsequently, active Jaks phosphor-
ylate tyrosine residues within the receptor cytoplasmic domain,
which form docking sites for STATs. Jaks then tyrosine-
phosphorylate receptor-bound STATs so that active STAT dimers
can finally translocate to the nucleus where they initiate
transcription by binding to response elements in the promoter of
a target gene [40].
IL-24 signals through two heterodimeric receptor complexes,
which share the short IL-20R2 chain but have distinct longer
IL-24 and Melanoma Cells
PLoS ONE | www.plosone.org 2 December 2007 | Issue 12 | e1300Figure 1. Western blot analysis of melanoma cells stimulated with IL-10-type cytokines IL-19, -20, and -24 shows no induction of STAT
phosphorylation. (A) 12 Mycoplasma-free melanoma cell lines, NHEM, and HaCaT cells were grown in 6-well plates and then stimulated for 45 min
with the indicated cytokines (75 ng/ml). Cells were lysed directly on ice by addition of 16Laemmli buffer. Transferred proteins were incubated over
night with anti P-Tyr STAT3 antibody, stripped and counter-stained with anti-actin antibody. (B) Stimulation of a selection of melanoma cells was
performed as described in (A) only that cytokines were added for different periods of time (5 min, 30 min, 3 h) before cells were harvested. Stripping
of western blot membranes prior to incubation with another phospho-specific antibody was performed as described in materials and methods.
doi:10.1371/journal.pone.0001300.g001
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PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e1300Figure 2. Kinetics and dose-dependence of IL-24 stimulation. HaCaT keratinocytes (positive control cells reacting to IL-24) and 2 selected
melanoma cell lines (MeWo and Wm35) were incubated with increasing amounts of IL-24 for 30 min (A) or with 25 ng/ml OSM or 200 ng/ml IL-24 for
different periods of time (B). Cell lysates were analysed by western blot with subsequent staining of P-STAT3, P-STAT1, and P-STAT5 followed by
STAT3 and actin counter stains.
doi:10.1371/journal.pone.0001300.g002
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signalling was detected in any of the melanoma cell lines following
IL-24(orIL-19and IL-20) treatment,theexpressionofthe 3possible
receptor chains was analysed by standard RT-PCR, quantitative
PCR (qPCR), Western Blot and FACS analyses. Primers used for
PCR reactions are listed in Table 1. First, standard RT-PCR was
performed using the equivalent of 100 ng RNA as starting material
(Fig. 3). Some but not all cell lines showed positive results for IL-22R
mRNAwhile hardlyanymRNAfor IL-20R1 and very low orabsent
mRNAs for IL-20R2 chains, the common subunit present in both
heterodimeric receptor complexes, were detected. As expected and
as previously published, HaCaT cells were positive for all 3 receptor
chains but negative for IL-24. IL-24 mRNA was detectable to
various levels in 6 out of 10 melanoma cell lines. The lower band
present in IL-24 RT-PCR samples corresponds to a splice variant,
which has been described before [41]. Previous reports have
suggested that melanoma cells express receptors for IL-24 although
it is unclear how this was analysed [28]. Performing RT-PCR with
very high cDNA input quantities (equivalent to 1 mg of RNA), we
alsofound all analysed cell lines tobe positive forthe 3 possibleIL-24
receptor chains (data not shown). However, lower starting amounts
of cDNA (10-100 ng/ml) reproducibly gave results as depicted
(Fig. 3) and these results matched well with those from qPCR shown
in Fig. 4. Again, in depth qPCR analysis was performed on different
amounts of input material to achieve a standard curve and a PCR
amplification efficiency of 100% for all samples. Fig. 4 shows
a summary of triplicate qPCR data from 3 independent experiments
using the equivalent of 12.5 ng RNA input material. mRNA
amounts of IL-24 were normalised to TBP and are shown in
correlationtoNHEM(Fig.4A).A375andIPC298showedmoderate
amounts of IL-24 mRNA with Wm9 reproducibly having IL-24
mRNA quantities ,50 fold higher than primary melanocytes.
Recently, it has been shown that primary keratinocytes harbour
high mRNA amounts for IL-20R2 and approximately 10-fold less
for IL-22R followed by very low levels of IL-20R1 mRNA [2].
Here, we found very similar expression patterns for the keratinocyte
cell line HaCaT. To better exemplify these largely divergent levelsof
the receptor chain mRNAs, copy numbers relative to those of the
house-keeping gene TBP, arbitrarily set to 100, are depicted in
Fig. 4C. This representation illustrates that HaCaT cells have
approximately 106more IL-20R2 than TBP mRNA while IL-22R
and IL-20R1 would correspond to mRNA copy numbers of ,15
and ,10, respectively, relative to the arbitrarily chosen 100 copies
for TBP. Following this theoretical exercise, it becomes evident that
the melanoma cell lines analysed here do not have significant
amounts of IL-24 receptor subunit mRNAs.
Since levels of mRNA do not necessarily reflect actual protein
expression, we analysed total cell lysates for the presence of IL-24
and its receptors by western blot (Fig. 5). Commercially available
antibodies recognised positive controls (Hek cells over-expressing the
respective receptor subunits and recombinant IL-24, R&D Systems)
at the expected molecular weights. However, endogenous levels of
surface receptors,even inHaCaT cells,were toolow to bedetectable
by western blot. For better comparison, lysates from transfected,
over-expressingcellshad tobediluted 5to 10-fold(Fig.5:seeloading
controlsstained with FIN-13oractinantibodies). Wealso performed
FACS analysis but could not detect any of the three IL-24 receptor
subunits on melanoma cells, HaCaT or NHEM cells using
commercially available antibodies (data not shown).
Figure 3. RT-PCR of IL-24 and its receptor subunits. Eight different
melanoma cell lines, primary NHEM and HaCaT cells were grown on
Petri dishes to a confluence of 80–90% before cells were harvested.
Total RNA was extracted, reverse transcribed and cDNA amounts
equivalent to 100 ng RNA were used as input material for amplifications
of IL-24, and the receptor subunits IL-20R1, -20R2, and -22R. To control
for equal starting amounts and loading, actin was amplified. Size
markers (bp) are indicated on the left.
doi:10.1371/journal.pone.0001300.g003
Table 1. Summary of primers used for quantitative real time PCR, standard RT-PCR amplifications and for IL-24 cloning.
..................................................................................................................................................
Target gene sense primer antisense primer application size (bp)
IL-20R1 TGTTGCTCCTGGCGG TTGATGGATAAGAAGGTGATGTTTG qPCR 91
TCAAACAGAACGTGGTCCCAGTG TCCGAGATATTGAGGGTGATAAAG RT-PCR 386
IL-20R2 TGTTGCCCCGTGGTGGT CTCCTCCCTTCTGCAGCTGAT qPCR 81
GCTGGTGCTCACTCACTGAAGGT TCTGTCTGGCTGAAGGCGCTGTA RT-PCR 406
IL-22R GAAGTCCTGCAACCTGACG GGTAGTGTGCTGCAGAGAGC qPCR 133
CCCCACTGGGACACTTTCTA TGGCCCTTTAGGTACTGTGG RT-PCR 243
IL-24 CAGGAGGAACACGAGACTGA GCACAACCATCTGCATTTGAGA qPCR 120
CAGTCGACACCATGAATTTTCAACAGAGGCTGC GAGGATCCCAGAGCTTGTAGAATTTCTGCATC RT-PCR 639
TBP ACCCAGCAGCATCACTGTT CGCTGGAACTCGTCTCACTA qPCR 120
Actin GCTCGTCGTCGACAACGGCT CAAACATGATCTGGGTCATCTTCTC RT-PCR 353
IL-24 CGGATCCGTACCATGAATTTTCAACAG CTGCTCGAGTCAGAGCTTGTAGAATT cloning of GST-mda7
IL-24 GCTCCTGCAGGTACCATGAATTTTCAACAG CTCCACCGGTGAGAGCTTGTAGAATTTCTGCATCC cloning of KDEL-IL24
Note: primers for amplification of IL20R1, R2, and IL-24 were as described by Wolk et al., 2002.
doi:10.1371/journal.pone.0001300.t001
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IL-24 and Melanoma Cells
PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1300Figure 4. Quantitative PCR for IL-24 and its 3 possible receptor subunits: absence of a functional IL-24 receptor on melanoma cells. RNA was
extracted and reverse transcribed as for standard RT-PCR. 12.5 ng RNA was used as input material followed by specific amplification of target genes
as indicated. Results are means +/2 STD of triplicate amplifications from three independent experiments using 3 independently extracted RNAs. Ct
values were normalized to those of the housekeeping gene TBP for each tested cell line. Calculations of relative expression values were performed
using the 2
2DDCt formula and expression levels were correlated to NHEM results for IL-24, (A) and to HaCaT for receptor subunits, (B), which were set
to 1. (C) The Ct value of the housekeeping gene TBP (in HaCaT cells) was arbitrarily set to represent 100 mRNA copies. The Ct values of IL-24 and the
three receptor subunits were converted accordingly in order to facilitate a clearer view of the relative amounts of the 4 target genes compared to the
housekeeping gene TBP.
doi:10.1371/journal.pone.0001300.g004
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PLoS ONE | www.plosone.org 6 December 2007 | Issue 12 | e1300Taken together, melanoma cell lines evaluated in this study did
not express sufficient amounts of specific receptor pairs, which
could mediate effects brought about by the cytokine IL-24. Hence,
the ‘‘bystander’’ effect that secreted IL-24 has been reported to
have on receptor-positive cancer and melanoma cells [34,42] is
difficult to reconcile with the lack of receptors found here.
Recombinant IL-24 has no effect on the proliferation
of melanoma cells
Exogenously administered recombinant cytokines (IL-19, -20, -22,
-24, and IFN-c) were analysed with regard to their growth-
modulating properties on a selection of melanoma cells (Fig. 6). No
growth-inhibiting or -stimulating effect was monitored when cells
were followed up for 5 days. IFN-c, which was included as
a control treatment known to inhibit the proliferation of
melanoma cells [39], showed the expected effects. Although
functional receptors are present on HaCaT cells, none of the
assayed cytokines influenced proliferation of the keratinocyte cell
line. HaCaT cells were confirmed by qPCR to express moderate
levels of IL-10R2, a receptor chain, which, together with IL-22R,
is required for IL-22-signalling (data not shown).
Having established that commercially available recombinant
cytokines expressed in mouse myeloma NSO cells (IL-24) or
bacteria (IL-19, -20) have no growth-modulating effect on
melanoma cells, we continued to examine different sources of
recombinant IL-24 for their impact on melanoma cells.
Sauane and colleagues [31] have shown that a GST-IL-24
fusion protein was able to induce apoptosis of prostate, pancreas
and breast cancer cell lines. Following this report, we produced
full-length GST-IL-24 to examine the fusion proteins’ potential to
drive melanoma cells into apoptosis. After considerable modifica-
tions to the published purification protocol in order to achieve
soluble protein, we were able to produce small quantities of pure
GST-fusion protein (Fig. 7A). Up to 250 ng/ml of this fusion
protein did not evoke a STAT3 phosphorylation in otherwise IL-
24-responsive HaCaT cells (data not shown), which was not
surprising given the presence of a bulky GST tag and the likely
altered conformation of the cytokine in such a recombinant fusion
protein. We then tested the effects of GST-IL-24 in comparison to
GST alone and untreated cells in Annexin V apoptosis assays.
Fig. 7B illustrates representative results on A375, Wm9, Wm35
and MeWo cells (results were reproduced 26 with different
batches of GST-IL-24). No substantial and reproducible induction
of apoptosis was detected after 48 or 72h of treatment in any of the
assayed melanoma cell lines. Hence, in our hands, bacterially
produced GST-IL-24 fusion protein did not induce notable
apoptosis of melanoma cells.
Assessment of IL-24-apoptosis-inducing properties
by transient over-expression
Since we did not detect any apoptosis-inducing properties of either
the bacterially produced GST-IL-24 or the commercially available
IL-24 (from mouse cells), we proceeded to produce FLAG-tagged
IL-24 from supernatants of transfected Hek cells (Hek-IL-24) as
has been described before (Fig. 8A) [7]. This mammalian source of
recombinant and soluble IL-24 has previously been reported to
elicit direct apoptosis as well as bystander effects in melanoma and
other cancer cells [30,34] while other studies failed to detect these
effects [33,43].
In agreement with the latter, we did not observe increased
apoptosis or inhibition of proliferation in A375, Wm9, MeWo or
HaCaT cells following incubation with crude Hek supernatant
containing approximately 40 ng/ml of recombinant IL-24 (Fig. 8B
and C) or with further affinity-purified FLAG-IL-24. In all
experiments, the growth inhibiting properties of Etoposide and
IFN-c were far more pronounced than any source of IL-24. As
a specificity control, we used IL-20, a related IL-10-type cytokine.
Neither one of the two soluble and extracellularly administered
cytokines had growth-modulating properties on melanoma cells.
Additionally, we incubated Wm35 cells with Hek-IL-24 super-
Figure 5. Western blot analysis of IL-24 and its receptors in total melanoma cell lysates. Total cell lysates of the depicted melanoma cell lines,
NHEM and HaCaT cells as well as control samples were analysed by Western blot to detect endogenous levels of IL-24 and its receptors. Positive
control samples: 100 ng of commercial recombinant IL-24 or Hek cells transiently transfected with the respective receptor subunit plasmids pcDEF3-
IL-20R1, pCEP4-IL20R2, or pEF-BosPuro-IL-22R as described before[7]. Lysates were loaded in parallel on either an 8% gel (IL-20R1 and IL22R) or a 10%
gel for detection of IL-20R2 and IL-24. After the first round of detection, blots were stripped and re-probed over night at 4uC with subsequent
antibodies. As transfected cells were strongly over-expressing the individual receptor chains, less lysates were loaded for the controls (see loading
controls stained with actin or FIN13). Commercially available antibodies recognize all positive controls but fail to detect specific bands correlating to
endogenous levels of receptors or IL-24.
doi:10.1371/journal.pone.0001300.g005
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PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e1300natants for 72 or 96h and counted dead cells after Trypan Blue
exclusion. No increase in apoptosis was observed (data not shown).
Finally and to test the possibility that only intracellularly over-
expressed IL-24 would render cancer cells more susceptible to
apoptosis, we transiently transfected melanoma and Hek cells with
either full length IL-24 or IL-20 as well as with a construct that
contains full length IL-24 together with a KDEL ER-targeting
sequence (KDEL) as several studies have recently postulated that
the apoptosis-inducing effects of IL-24 are mainly mediated by
triggering ER stress responses [33,36]. This has been shown
Figure 6. Influence of IL-10-type cytokines on the proliferation of melanoma cells. Four different melanoma cell lines and HaCaT cells were seeded
in their appropriate growth media supplemented with 1% FCS (96-well plates) and were incubated with 100 ng/ml of IL-19, -20, -22, -24 or IFN-c.A t
day 0, 2, and 5, 5 ml of WST-1 reagent was added for 40 min to each well before absorbance at 450 nm was measured. Shown are results of triplicate
wells from three different experiments +/2 STD.
doi:10.1371/journal.pone.0001300.g006
IL-24 and Melanoma Cells
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expression system. Depending on the multiplicity of infection, it
can be speculated that IL-24 is largely over-expressed from within
the cell by such a regimen and this is likely to induce ER stress
responses, which culminate in cell death. Using transient over-
expression but explicitly circumventing the adenoviral backbone,
we have used standard pcDNA5 vectors to introduce the
recombinant proteins into cells. Fig. 9 depicts results for 2
melanoma cell lines and Hek cells, which served as a negative
control as these non-cancer cells should not die under the
influence of IL-24 [36]. Etoposide, a potent inducer of apoptosis,
was included as a positive control for the Annexin V-FACS assays.
Although there is a dose-dependent increase of cell death,
especially in A375 cells, this increase was also observed for control
transfections (IL-20 and pcDNA alone). Western blots below the
bar diagrams illustrate that recombinant proteins were dose-
dependently over-expressed in the respective target cell lysates.
Overall and relative to control treatments, no cancer-specific
apoptosis-inducing properties of IL-24, even when over-expressed
from within melanoma cells, were recorded.
DISCUSSION
Over the past decade numerous publications have argued that IL-
24, an IL-10-family cytokine, selectively kills a vast variety of
cancer cells, in vivo and in vitro, leaving healthy cells unharmed (for
recent reviews: [8,34]). These astonishing attributes have served as
a basis for the development of a therapeutic adenovirus delivering
IL-24 (Ad-IL-24) to cancer patients, a form of treatment that is
currently being assessed in clinical trials (Introgen company
homepage). It is believed that the combination of IL-24 with
adenoviral over-expression represents a promising treatment
option for various solid cancers [44]. However, conflicting data
exist as to whether other recombinant forms of IL-24 (bacterial
GST-fusion protein, baculovirus-expressed IL-24, secreted IL-24
from transfected mammalian cells) have this apoptosis-inducing
property and whether these effects are receptor-dependent or not.
By using cell lines deficient of individual components of the Jak/
STAT pathway or by using Jak inhibitors it was demonstrated that
initial IL-24-induced apoptosis of cancer cells is independent of
Jak/STAT signaling pathways and thus independent of receptor
engagement [10,45]. However, there is also evidence that IL-24
mediates bystander effects via receptor-mediated Jak/STAT
signaling on receptor-positive surrounding cancer cells that come
into contact with the secreted cytokine IL-24 [10,27,28].
Focusing on melanoma cells and on the ‘‘cytokine-like’’
properties of IL-24, we first stimulated a panel of 14 different
cell lines with commercially available recombinant IL-24.
Surprisingly, none of the tested cell lines, except HaCaT
keratinocytes, showed phosphorylation of STAT3, also not 3 cell
lines (A375, Wm35, and MeWo) that had previously been
described to be receptor-positive and to react to an IL-24 stimulus
Figure 7. Recombinant GST-IL-24 and its effect on the growth of selected melanoma cells. (A) GST-IL-24 was cloned and purified as described in
materials and methods. Samples from the flow through, wash and eluted fractions were analysed on a SDS-PAGE followed by Coomassie staining.
Western blots of recombinant GST-IL-24 showing specific staining with anti-GST and anti-IL-24 antibodies. (B) AnnexinV-apoptosis assay on cells that
were incubated with 40 mg/ml recombinant fusion proteins for 48 h. GST-IL-24 does not substantially increase the number of apoptotic melanoma
cells relative to control treatments.
doi:10.1371/journal.pone.0001300.g007
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PLoS ONE | www.plosone.org 9 December 2007 | Issue 12 | e1300Figure 8. Mammalian IL-24 secreted and purified from transfected Hek cells does not induce apoptosis in melanoma cells. (A) Western blot
analysis of supernatants from Hek cells transfected with mock vector pCEP, pCEP-IL-20, or pCEP-IL-24. (B) Proliferation assay of 3 selected cell lines
that were incubated for 72 h with at approximately 40 ng/ml of IL-20 or IL-24 from transfected Hek cell supernatants. (C) Density blots of FACS
apoptosis assay of selected cell lines incubated for 72 h with the indicated Hek supernatants, IFN-c, or Etoposide, which served as positive control
inducing profound apoptosis in most cell lines. The percentage of dead cells is depicted as bar diagrams on the right panel. Neither Hek-produced IL-
20 nor IL-24 increase apoptosis in melanoma cells.
doi:10.1371/journal.pone.0001300.g008
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scored by a rather unspecific immunofluorescence assay, in which
translocation of STAT3 to the nucleus was enumerated [28]. Here
we show that melanoma cells did not respond to IL-24, neither
when up to 800 ng/ml of cytokine was administered, nor over
different periods of time. This led us to investigate receptor
expression on these cells. Using standard RT-PCR, qPCR,
Western Blot and FACS analysis, we could not detect mRNA or
protein quantities sufficient to qualify for a functional IL-24
receptor. Consequently, our cytokine stimulation data correspond
to the receptor expression studies: HaCaT keratinocytes express
(to various degrees) IL-20R1, IL-20R2, and IL-22R receptor
chains and readily react to IL-19, IL-20, and IL-24 stimulation
with phosphorylation of (predominantly) STAT3. In contrast,
none of the melanoma cell lines expressed sufficient amounts of
receptors for IL-10-type cytokines (IL-19, -20, and -24) and do
therefore not react to these cytokines by activation of the Jak/
STAT pathway.
In agreement with Kunz et al. [2], we also found that
keratinocytes express the IL-20R2 chain at very high levels (10
fold higher than the reference gene TBP). Much lower (0.1 fold
TBP) was the expression of IL-22R followed by even lower
amounts of IL-20R1 suggesting that STAT3 activation of cultured
keratinocytes is mediated by engagement of the type II receptor
IL-22R/IL-20R2. IL-19 only signals through the type I receptor
IL-20R1/IL-20R2 and since IL-20R1 is the limiting subunit on
HaCaT cells, IL-19 evoked the weakest P-STAT3 signals.
However, and in contrast to a recent report [2], we also observed
a weak but detectable activation of STAT1 and STAT5 following
30 min of IL-24 or IL-20 stimulation of HaCaT cells. This could
be due to the higher amounts of IL-24 that were used in our assays
(100 ng/ml versus 10 ng/ml) (Fig. 2).
The receptor chains IL-20R1 and IL-22R seem to be widely
expressed in many tissues, nevertheless, expression of a functional
receptor for IL-24 depends on the presence of IL-20R2, the
common chain for both receptor pairs [7,46]. Expression of IL-
20R1 has been reported in tissues such as skin, lung, testis, and
ovary [45], however, most of the IL-24 receptor expression studies
relied on RT-PCR, which is neither quantitative nor does it
establish the presence of corresponding proteins and as such,
functional receptors. Relative to primary NHEM cells, only 3
melanoma cell lines were found to express IL-24 (A375, IPC298,
and Wm9). Interestingly, Wm9, a cell line established from a late
stage metastatic melanoma patient [47], harbours very large
mRNA quantities for IL-24 while Wm35, an early stage cell line
derived from the same patient hardly showed any expression of IL-
24, indicating that IL-24 expression is increased rather than
decreased during melanoma progression. This contrasts with
previous reports where IL-24 was shown to disappear with
progression of melanoma in primary patient samples [13,14].
However, Wm9 and Wm35 were the only paired samples
available for the current study and expression patterns of IL-24
and other proteins might be different between established cell lines
and primary material.
Considering the calculations given by Kunz et al. [2] together
with our very similar qPCR results it is sensible to assume that
melanoma cells (and also immune cells) do not express functional
receptor pairs that could transmit signals emanating from IL-24,
a notion which is further substantiated by the lack of STAT3
activation in these cell types following IL-24 treatment. This
throws into doubt whether IL-24 can exert so-called bystander
effects on melanoma cells as these are believed to depend on the
presence of receptors [28,30].
Figure 9. Transient over-expression of IL-24 and ER-targeted IL-24
does not increase apoptosis. Cells were transiently transfected with 2
different amounts of DNA encoding mock vector alone (pcDNA),
pcDNA-IL-24 (IL-24), pcDNA-KDEL-IL-24 (KDEL) or pcDNA-IL-20 (IL-20)
using nucleofection technology from Amaxa 720h after transfection,
cells were processed for AnnexinV-staining detected by FACS. Percent
dead cells are depicted in the bar diagrams (duplicates from 3
independent experiments). Below, control western blots show the
specific over-expression of the respective proteins.
doi:10.1371/journal.pone.0001300.g009
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induce apoptosis of cancer cells, we reasoned that delivery modes
other than adenovirus-mediated over-expression of IL-24 should
also be able to elicit cell death. Sauane and colleagues [32] have
argued that GST-IL-24 is unspecifically taken up by target cells via
the GST moiety [48] and that this recombinant fusion protein
specifically kills cancer cells of different origins. To investigate this
further, we produced bacterially expressed GST-IL-24, which
became soluble only with major modifications to the published
protocol [31] (and Materials and Methods in this paper). GST-
mda7 failed to significantly modulate growth characteristics of 4
different melanoma cell lines (Fig. 7).
Next, we tested the properties of IL-24 produced from
transfected Hek cells. Using crude or affinity purified Hek-IL-24,
again no increase in apoptosis or reduced proliferation was
observed relative to untreated cells or cells treated with
accordingly produced IL-20 (Fig. 8) and this was not surprising
as the tested melanoma cell lines did not express functional IL-24
receptors (Figs. 3 and 4). The Hek-IL-24 was, however, able to
evoke phosphorylation of STAT3 in receptor-positive HaCaT cells
(Fig. 1A) indicating the functionality of this form of cytokine.
Transient or stable inducible over-expression of proteins can
trigger ER stress responses, which ultimately drive the host cell
into apoptosis [49]. Depending on the multiplicity of infection
(moi), the efficient delivery of IL-24 by an adenoviral expression
system is likely to induce UPR or ER stress and several reports
have already confirmed this notion. In view of this, it has been
shown that Ad-IL-24 directly interacts with the chaperone BiP/
Grp78, a major player in ER stress response pathways [36]. Also,
transduction of lung cancer cells with Ad-IL-24 increased
expression of ER stress-related proteins such as BiP/Grp78,
GADD34, XBP-1 and transfection of cancer cells with ER-
targeted IL-24 plasmids elicited increased apoptosis compared to
proteins targeted to the nucleus or membrane [33]. Transient
intracellular over-expression of IL-24 by methods other than viral
delivery should therefore result in increased cancer cell death
provided that IL-24 itself has the ability to specifically initiate
events necessary for apoptosis. Since transfection efficiencies of
melanoma cells are generally very low, we first tested several
commonly used reagents and protocols. Quantification of
transfected cells was performed following transient transfection
of recombinant GFP or GFP-IL24 and subsequent FACS analysis
or visual counting of fluorescent cells under the microscope.
Nucleofection in combination with optimised cell line-specific
protocols (Amaxa) yielded highest efficiencies (20–30%) with very
little spontaneous cell death (data not shown). Although these
transfection efficiencies were acceptable for melanoma cells, they
are, however, not optimal and certainly far lower than those
achieved with adenoviral expression of IL-24. Nevertheless, 20–
30% transfected cells should be sufficient to detect specific and
significant increases of apoptosis. Using nucleofection, we in-
troduced wt-IL-24, ER-targeted IL-24 (KDEL) as well as wt-IL-20
into A375 and MeWo cells. Hek cells served as a non cancer
control cell line that should be resistant to IL-24-mediated killing.
Even up to 20 mg of transfected IL-24 DNA did not result in
a surplus of apoptotic cells compared to control experiments, once
more demonstrating that even intracellular over-expression does
not lead to a specific killing of melanoma cells in response to full
length or ER-targeted IL-24.
In summary, the ability of IL-24 to selectively and efficiently
induce apoptosis of melanoma and many other cancer cells could
not be reproduced using either commercial IL-24, bacterially
expressed GST-IL-24, IL-24 secreted from transfected Hek cells,
or transient over-expression of different IL-24 constructs. As none
of the assayed melanoma cell lines expressed functional receptor
pairs for IL-24, it was not surprising that Hek-IL-24 did not trigger
increased cell death and in view of this, it seems questionable
whether secreted IL-24 from transfected or infected cells could
induce so-called bystander effects on receptor-negative melanoma
cells. Finally, we could not detect significant cell death upon
intracellular over-expression of IL-24 suggesting that the beneficial
outcome seen after transduction of cancer cells with Ad-IL-24 may
be due to combinatorialeffects of IL-24 over-expression achieved via
cancer-targeted adenovirus infection only. Adenoviral infection may
leadtoanupregulationofinterferonsand/orIL-24receptors,which,
in synergy with over-expressed IL-24 could possibly account for the
previously observed therapeutic effects of Ad-IL-24. In view of this,
care should be taken when attributing the cytokine IL-24 itself with
apoptosis-inducing properties on melanoma cells.
MATERIALS AND METHODS
Cell culture
In total, 12 mycoplasma-free melanoma cell lines were analysed:
A375 (ATCC, Wesel, Germany), Wm9, Wm35, Wm239,
Wm902B, SKMel30, MelJuso, MelIm, IPC298, G361, IGR37,
and MeWo. All cell lines were cultured in RPMI, supplemented
with 10% FCS, 50 mg/ml penicillin, 100 mg/ml streptomycin,
0.5 mM L-glutamin in a humidified atmosphere with 5% CO2.
The keratinocyte cell line HaCaT was grown in DMEM
supplemented with 10% FCS, 50 mg/ml penicillin, and 100 mg/
ml streptomycin; normal human melanocytes (NHEM) (Clonetics,
Cambrex Bio Science, Belgium) were maintained according to the
supplier’s instructions in complete MGM-4 medium. Hek293 cells
were grown in DMEM (supplemented with 10% FCS and
antibiotics as above). All cultured cells were routinely tested to
be negative for mycoplasma contamination.
Reagents and antibodies
The following antibodies were used for protein detection in
western blots: STAT3, STAT1 (BD Transduction Laboratories,
BD Biosciences, Erembodegem, Belgium); STAT5 (Santa Cruz);
P-STAT3-Tyr705; P-STAT1-Tyr701, P-STAT5-Tyr694 (Cell
Signaling Technologies, Frankfurt, Germany). HRP-labeled
secondary antibodies were purchased from Dako (Heverlee,
Belgium). Antibodies directed against Fin13 (BD Transduction
Laboratories, BD Biosciences) or actin (Chemicon) were used as
loading controls where applicable.
For stimulation experiments, cells were treated for the indicated
times with different concentrations of recombinant cytokines IL-
19, -20, -22 (R&D Systems, produced in E. coli), IL-24 (R&D
Systems, produced from mouse myeloma cells), OSM, IFN-c,I F N -
a (Peprotech, London, UK), GST-IL-24 or Hek-IL-24 (see below).
Western Blot
Cells were seeded in appropriate culture vessels and were grown to
approximately 90% density, washed 16 with PBS, followed by
direct lysis on ice with Laemmli buffer (20% glycerine, 10% ß-
mercaptoethanol, 4% SDS, 0,125M Tris-HCl, pH 6.8, 0.002%
bromophenol blue); generally 400 ml were used for 1 well from a 6-
well plate. Alternatively, cells were lysed in lysis buffer (1% Triton
X-100, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM NaF,
1m MN a 3VO4, 10 mM PMSF, 1 mM benzaminidine, 5 mg/ml
aprotinin, 3 mg/ml pepstatin, 5 mg/ml leupetpin) and the
concentration of total cell lysates was determined by Bradford
assay (BioRad, California, USA). Fifty mg of total lysates were
boiled for 5 min at 95uC and loaded on a 10% SDS-PAGE gel.
Proteins were transferred onto a PVDF membrane and detected
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stripped for 30 min at 70uC in 62.5 mM Tris, 2% SDS, pH 6.7
and 78 ml ß-mercaptoethanol/10 ml buffer. Alternatively, for re-
probing with phospho-specific antibodies, blots were stripped for
4–5 h at room temperature in 2 M glycine, pH 2.5 with 1 g of
SDS for each blot, washed extensively in H2O, blocked for 1 h
(TBS+5% BSA), and incubated with the next antibody. For highly
sensitive detection of chemiluminescent signals, the ECL solution
pCA was used as described [50].
Proliferation and apoptosis assays
For proliferation assays 3000 cells/well were seeded in quadru-
plicate wells (96 well plates). Increasing concentrations of cytokines
or other compounds were added for different lengths of time as
indicated. WST-1 reagent (5 ml/well) (Roche Biochemicals, Basel,
Switzerland) was added for 30 min at 37uC and absorbance was
measured at 450 nm.
For apoptosis assays, 750 000 cells were grown in quadruplicate
in 6-well plates with addition of GST, GST-IL-24, Hek-control
supernatant (Hek-ctrl), Hek-IL-24 or commercial recombinant
cytokines for 48h or 72h. Cells were harvested and processed as
described in the Annexin V-FITC Apoptosis Detection kit II
manual (BD Transduction Laboratories, BD Biosciences, Erem-
bodegem, Belgium). FITC and Propidiumiodide fluorescences
were measured using a BD FACS Canto II (Becton Dickinson).
Alternatively, cells were transiently transfected with pcDNA vector
(mock control), pcDNA expressing full length IL-24, full length IL-
20, or a pcDNA construct expressing IL-24 together with a KDEL
sequence, which targets recombinant proteins to the endoplasmic
reticulum (ER). Cells were transfected using the Nucleofector
technology (Amaxa, Cologne, Germany) according to optimised
protocols provided by Amaxa for Hek, A375 and Mewo cell lines
and apoptosis was measured as described above after 48 and 72h.
To control for successful transient expression of transfected
proteins, correspondingly treated samples were washed with PBS
and lysed directly on ice with 16 Laemmli buffer followed by
western blot analysis.
Gene expression analysis
Total RNA was extracted from cells grown on a 10 cm petri dish
(,90% confluent) using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions with
additional on-column DNase digestion. 1 mg of RNA was reverse
transcribed using the Thermoscript RT PCR System (Invitrogen)
and 50 mM oligo(dT)20 for priming. The newly synthesised cDNA
was additionally treated with 2 units of RNase H at 37uC for
30 min.
Amplification of the target genes with standard RT-PCR was
performed on cDNA amounts equivalent to either 100 ng or
10 ng of RNA input. A 50 ml reaction consisted of 16PCR buffer,
1.5 mM MgCl2, 0.2 mM dNTP mix, 10 pmol of each of the
corresponding primers (Table 1) and 1 U/reaction of PlatinumH
Taq DNA Polymerase (Invitrogen).
Quantitative real time PCR (qPCR) was carried out on a MyiQ
Single-Color Real-Time PCR Detection System (BIORAD). The
reaction volume was 25 ml containing cDNA diluted to the
equivalent of 12.5 ng RNA, 10 pmol of each primer, and 12.5 ml
of iQ SYBR Green Supermix (BIORAD). The thermal cycling
conditions for all qPCR assays included an initial enzyme
activation step at 95uC for 3 min, followed by 40 cycles of
denaturation at 95uC for 10 s and annealing at 60uC for 30 s. The
PCR for the housekeeping gene TATA-binding protein (TBP),
which was found to have medium but constant/similar mRNA
levels across the different melanoma cell lines, and the target genes
were performed in parallel for each sample. All samples were run
in triplicate and in 3 independent experiments. The primers used
for the amplification of the target genes are listed in Table 1.
Standard curves with four 10-fold serial dilutions (16, 0.16, 0.016
and 0.0016) were produced to ensure that the amplification
efficiencies for all primer pairs used were 100%. The specificity of
real-time PCR was verified by melting curve analysis. The mRNA
levels of the target genes were normalized to the relative amounts
of the housekeeping gene TBP. The 2
2DDCt method was used to
calculate the fold-relationships in gene expression between the
tested melanoma lines [51].
Construction and purification of GST-IL-24 fusion
protein
For generation of GST-IL-24 (or synonymously GST-mda7)
fusion proteins, full length IL-24 was amplified from RNA
extracted with the RNeasy mini kit (Qiagen, Hilden, Germany)
from HaCaT cells using RT-PCR primers listed in Table 1, which
incorporated BamHI and XhoI restriction sites for cloning into
pGEX-5X1 vector (Amersham, GE Healthcare). The fusion
protein was intentionally similar to the one described by Sauane
et al. (2004) and therefore the signal peptide was included although
this should not exert any function when situated between the GST
and the IL-24 moiety. GST fusion protein (or GST alone) was
produced in BL21(DE3) bacteria. A pre-culture of 20 ml (LB
containing 2% glucose and 50 ug/ml ampicillin) was grown at
37uCt oa nO D 600 of 1.4 and then inoculated into 200 ml of LB
(+2% glucose) medium. When the OD600 reached 0.4, tempera-
ture was dropped to 18uC. At an OD600 of 0.6, protein production
was induced with 0.5 mM IPTG for 3 h at 18uC. Cells were
harvested by 15 min centrifugation at 5000 rpm and the pellet was
lysed in 40 ml lysis buffer (20 mM Tris pH7.5, 50 mM NaCl,
0.2% Igepal CA 630, 1 mg/ml lysozyme, 1 tablet complete
protease inhibitor cocktail (Roche Biochemicals) in 50 ml lysis
buffer) followed by 4 freeze (15 min dry ice)/thaw (10 min 37uC)
cycles. 25 ug/ml DNase was added for 30 min at room
temperature to the lysate, which was then clarified by 30 min
centrifugation at 4uC. Subsequently, GST-containing proteins
were affinity-purified by incubation with washed and equilibrated
glutathione sepharose 4B slurry (Amersham Biosciences) (750 ml)
overnight at 4uC. The sepharose was pelleted at 1000 rpm for
5 min (4uC) and washed 4615 min with 7.5 ml PBS each. Fusion
proteins were eluted with 500 ml elution buffer (10 mM reduced
glutathione in 50 mM Tris-HCl, pH 8.0) for 90 min rotating at
room temperature followed by a second and third elution for
45 min each. Quality and purity of fusion proteins was verified on
Coomassie gels and by western blot. Protein concentrations were
determined using a standard Bradford assay (Biorad).
Construction of ER-targeted recombinant IL-24
proteins
For ease of subsequent cloning steps, we modified the pcDNA5/
FRT/TO vector (Invitrogen) by introducing a new multiple
cloning site (MCS) containing restriction sites for the following
enzymes: BsiWI, AscI, SbfI, SgrAI, FseI, PacI, and SwaI. For this,
oligos with HindIII and NotI overhangs were synthesised (Euro-
gentec, Belgium), annealed, and then ligated into HindIII- and
NotI-opened pcDNA5/FRT/TO resulting in the modified vector
pcDNAmod. Forward oligo: 59AGCTTCGTACGAAGGCGCG-
CCTACCTGCAGGTTTCACCGGTGTAAGGCC GGCCT-
GATTAATTAAGTAATTTAAATGC, Reverse oligo: 59GGCC-
GCATTT AAATTACTTAATTAATCAGGCCGGCCTTACA-
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Using standard cloning procedures, full length IL-24 was inserted
into pcDNAmod. For this, the target was PCR-amplified from
pGEX-5X1/IL-24 (described above) using primers listed in
Table 1, which had a SbfI and a SgrAI site incorporated resulting
in pcDNA-IL-24. Accordingly, pcDNA-IL-20 was generated; the
IL-20 sequence was amplified from a previously described vector:
pCEP-FLAG-IL-20 [7]. To generate vectors that target IL-24
expression to the endoplasmic reticulum (ER), a KDEL retention
signal sequence was inserted into the FseI/PacI-opened pcDNA-
IL-24 via a synthesised and annealed oligo harbouring FseI and
PacI overhangs. Forward oligo: 59 CCGGTAGTAAAGATGAA-
CTTTAATTAAT, Reverse oligo: 59 TAATTAAAGTTCATCT-
TTACTACCGGCCGG. All generated recombinant plasmids
were sequenced (GATC, Konstanz, Germany) to ensure correct
orientations and sequences of inserts.
Production and quantification of human IL-24 (Hek-
IL-24)
Hek293 cells were transiently transfected with pCEP-FLAG
vector, pCEP-FLAG-IL-20, or pCEP-FLAG-IL-24 vector as
described before [7]. Three to four days after transfection,
supernatants were harvested and supplemented with protease
inhibitor cocktail (Roche Biochemicals, Switzerland). Supernatants
containing the recombinant proteins IL-20 and IL-24 were
affinity-purified and further concentrated using anti-FLAG M2
affinity gel (Sigma) according to instructions supplied with the
product. Supernatants and cell pellets from transfected Hek cells
were analysed by Western blot and ELISA. To determine the
concentrations of IL-24, anti-IL-24 antibody (R&D Systems) was
coated over night in PBS on Microlon ELISA plates (Greiner,
Belgium). Plates were washed, blocked and incubated with serial
dilutions of IL-24-containing supernatants for 2 h at room
temperature (RT). After washing, biotinylated anti IL-24 antibody
(R&D Systems) was added for 2 h at RT. Subsequent incubation
with Streptavidin-HRP (20 min, RT) was followed by addition of
Tetramethylbenzidine(TNB)substrate.Reactionswerestoppedwith
2N H2SO4 and absorbances were measured at 450 nm. Concentra-
tions of affinity-purified IL-24 ranged between 3–8 ng/ml.
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